WO2023062595 - TREATMENT OF SUBJECTS HAVING PULMONARY ARTERIAL HYPERTENSION WITH RODATRISTAT ETHYL
National phase entry is expected:
Publication Number
WO/2023/062595
Publication Date
20.04.2023
International Application No.
PCT/IB2022/059864
International Filing Date
14.10.2022
Title **
[English]
TREATMENT OF SUBJECTS HAVING PULMONARY ARTERIAL HYPERTENSION WITH RODATRISTAT ETHYL
[French]
TRAITEMENT DE SUJETS ATTEINTS D'HYPERTENSION ARTÉRIELLE PULMONAIRE À L'AIDE DE RODATRISTAT ÉTHYLE
Applicants **
ALTAVANT SCIENCES GMBH
Viadukstrasse 8
4051 Basel, CH
Inventors
LAZARUS, Howard
c/o Altavant Sciences, Inc.
6501 Weston Parkway, Suite 330
Cary, North Carolina 27513, US
DENNING, Jill
c/o Altavant Sciences, Inc.
6501 Weston Parkway, Suite 330
Cary, North Carolina 27513, US
WRING, Stephen
c/o Altavant Sciences, Inc.
6501 Weston Parkway, Suite 330
Cary, North Carolina 27513, US
SYMONDS, William
c/o Altavant Sciences, Inc.
6501 Weston Parkway, Suite 330
Cary, North Carolina 27513, US
PALACIOS, Michelle
c/o Altavant Sciences, Inc.
6501 Weston Parkway, Suite 330
Cary, North Carolina 27513, US
Priority Data
63/255,818
14.10.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2524 | |
| EPO | Filing, Examination | 25239 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 14110 |
Total: 43039 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The disclosure relates to methods for treating a subject diagnosed with pulmonary arterial hypertension (PAH). Methods of lowering pulmonary vascular resistance, improving exercise capacity, and/or slowing disease progression by administering a therapeutic amount of rodatristat ethyl to the subject, are disclosed. Methods of reducing incidence of mortality, occurrence of hospitalizations, hemodynamics, and/or right atrial size by administering a therapeutic amount of rodatristat ethyl to the subject, are also disclosed.[French]
L'invention concerne des méthodes de traitement d'un sujet chez lequel on a diagnostiqué une hypertension artérielle pulmonaire (HTAP). L'invention concerne également des méthodes d'abaissement de la résistance vasculaire pulmonaire, d'amélioration de la capacité d'exercice, et/ou de ralentissement de la progression d'une maladie par l'administration d'une dose thérapeutique de rodatristat éthyle au sujet. L'invention concerne en outre des procédés de réduction de l'incidence de la mortalité, du nombre d'hospitalisations, de l'hémodynamique et/ou de la taille auriculaire droite par l'administration d'une dose thérapeutique de rodatristat éthyle au sujet.